About OculisOculis is a clinical-stage, privately held, pharmaceutical development company focusing on ophthalmic drugs and novel drug delivery to the eye.
The Oculis drug delivery platform consists of a novel technique to facilitate drug absorption to both anterior and posterior parts of the eye. The advantage is a drug delivery system where diseases of the posterior part of the eye can be treated with a simple topical application. The Oculis drug delivery platform allows diseases such as DME (diabetic macular edema) at the posterior part of the eye to be treated with a non-invasive topical application. Furthermore, the technique has been demonstrated to allow diseases at the anterior part of the eye to be treated with a reduced number of topical applications compared to conventional eye-drops.
Founders: Einar Stefansson, MD, PhD and Thorsteinn Loftsson, PhD
CEO: Pall Ragnar Johnnesson
CCO: (Regulatory and Clinical) Gudrun Marta Asgrimsdottir, MSc
CSO: Thorsteinn Loftsson, PhD
Please click here for.
Please click here for clinical trial information.
Tweets by Amgen
Currently, there are no jobs for this employer on BioSpace.
Browse jobs with BioSpace Featured Employers here.